MicroPort EP Receives FireMagic™ TrueForce™ Ablation Catheter Approval

Shanghai, China, 19 September 2023 — Recently, MicroPort EP announced that its FireMagic™ TrueForce™ Ablation Catheter (TrueForce™ Ablation Catheter) had successfully obtained CE certification in the European Union and UKCA certification in the United Kingdom.

The TrueForce™ Ablation Catheter, when used alongside MicroPort EP’s Columbus™ 3D EP Navigation System and OptimAblate™ Cardiac Generator, is employed for the treatment of drug-refractory recurrent symptomatic paroxysmal atrial fibrillation.1

When working in conjunction with the Columbus™ 3D EP Navigation System, the TrueForce™ Ablation Catheter can accurately indicate the force value and direction of catheter-tissue contact, establish an energy index, provide ablation energy indications, and offer real-time feedback on the formation of ablation lesions.2

In 2022, the TrueForce™ Ablation Catheter received its initial approval from the NMPA in China. Since then, it has been employed in over 400 radiofrequency ablation surgeries. The recent acquisition of CE certification and UKCA certification marks a significant stride in MicroPort EP’s journey. In the future, MicroPort EP will continue to provide high-quality and comprehensive solutions for electrophysiological diagnoses and treatment to more patients worldwide.

About MicroPortEP

Founded in Shanghai in 2010, Shanghai MicroPort EP MedTech Co., Ltd. (“MicroPort EP”, stock code: 688351.SH), a joint-stock subsidiary of MicroPort Scientific Corporation (“MicroPort®”, stock code: 00853.HK), is a global medical devices company focusing on the development, manufacturing, and marketing of minimally invasive medical devices for the treatment of cardiac arrhythmia disease. It has developed a family of advanced cardiac ablation catheters, diagnostic catheters, and 3D navigation systems. These products are used by hundreds of physicians at over 600 hospitals across China and beyond. At MicroPort EP, we strive to provide integrated therapeutic solutions to apply precise navigation on interventional procedures, dedicated to providing high quality therapeutic solutions to patients and physicians across the globe.

More information is available at www.everpace.com.


  1. Medical Device Technology Evaluation Center (NMPA). Medical device product registration technical review report. Shanghai: Shanghai Minimally Invasive Electrophysiology Medical Technology Co., Ltd.; 2022 Nov p. 1–12.
  2. Zhang R, Chu H, Liu S, Yang B, Han B, Xiao X, et al. Catheter ablation of atrial fibrillation using FireMagic TrueForce ablation catheter: The TRUEFORCE trial. Pacing and Clinical Electrophysiology. 2023;46(8):986–93.